MDS clinical trials are the most effective way to evaluate new treatments for myelodysplastic syndromes. Most trials are designed to compare an emerging therapy to a treatment that is already recommended for MDS patients. This helps researchers determine if the new treatment is more effective than the current standard of care, and also whether one treatment causes fewer side effects than the other.
Moffitt Cancer Center hosts a wide range of MDS clinical trials on a regular basis. As a member of the Bone Marrow Failure Disease Consortium – a collaborative research group dedicated to the study of myelodysplastic syndromes and similar diseases – Moffitt has received many coveted research grants from the National Institutes of Health. As a result, our team has had the ability to investigate:
- Novel chemotherapy agents and combinations of multiple agents
- Supportive care options, such as online and social media-based support groups for transplant recipients
- Targeted medications that have the potential to reduce the likelihood of recurrence after MDS treatment
Through our MDS clinical trials, Moffitt has given countless patients a way to benefit from innovative treatments that aren’t yet available in other settings. In some cases, these treatments opened new doors for patients who didn’t respond to traditional therapies; in other cases, these treatments provided hope to patients who were not eligible for bone marrow transplants. While no patient is ever required to participate in a clinical trial, our malignant hematologists can help match interested individuals with trials that meet their specific needs.